000			04078nam a22003855i 4500
001			82242
003			ES-MaUEC
005			20230207040403.0
007			cr nn 008mamaa
008			150116s2015 gw | s |||| 0|eng d
020			_a9783319125053
024	7		_a10.1007/978-3-319-12505-3 _2doi
050		4	_aRC644 _b2015 EB
245	1	0	_aHodgkin Lymphoma : _bA Comprehensive Overview _cedited by Andreas Engert, Anas Younes.
250			_a2nd ed. 2015.
260			_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (XV, 437 páginas) _b82 ilustraciones, 50 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aHematologic Malignancies _x2197-9766
505	0		_aPart I: From Hodgkinâ€{u3824}isease to Hodgkin Lymphoma: Epidemiology -- The role of viruses in the genesis of Hodgkin Lymphoma -- Pathology and molecular pathology of Hodgkin Lymphoma -- Microenvironment, cross-talk and immune escape mechanisms -- What will we learn from Genomics and Proteomics in Hodgkin Lymphoma? Part II: Diagnosis and treatment:Clinical evaluation -- Functional imaging -- Prognostic factors -- Principles of radiation techniques in Hodgkin Lymphoma -- Principles of chemotherapy in Hodgkin Lymphoma -- Treatment of early favorable Hodgkin Lymphoma -- Treatment of early unfavorable Hodgkin Lymphoma -- Treatment of advanced-stage Hodgkin Lymphoma -- Relapsed and refractory Hodgkin Lymphoma -- Paediatric Hodgkin Lymphoma. Part III: Special Clinical Situations: Lymphocyte-predominant Hodgkin Lymphoma -- The management of Hodgkin Lymphoma during pregnancy -- The management of HIV-Hodgkin Lymphoma -- The management of elderly patients withÂ{u8BE4}dgkin Lymphoma -- Allogeneic transplantation for relapsed of Hodgkin Lymphoma -- Targeting CD 30 -- Other new agents for patients with Hodgkin Lymphoma. Part IV: Survivorship: Quality of Life in Hodgkin Lymphoma -- Second malignancy risk after treatment of Hodgkin Lymphoma -- Cardiovascular and pulmonary late effects -- Gonadal dysfunction and fertility preservationÂ{u2829}in Hodgkin Lymphoma patients. Â{u2802}Â{u2802}Â{u2802}Â{u2802}Â{uE000}
520	3		_aThis book examines in detail the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the management appropriate in special clinical circumstances, including in the elderly, pregnant women, and those with lymphocyte-predominant disease. Careful attention is devoted to the emerging individually tailored treatment strategies that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The second edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by the key opinion leaders to reflect recent progress in the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma. .
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aLinfomas _0(OCoLC)958601 _2embne _0 _9668066
650	1	7	_aSalud pública _0 _2embne _9138408
700	1		_aEngert, Andreas _eeditor literario _995040 _0Local
700	1		_aYounes, Anas _eeditor literario _995041 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-12505-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12908824 _b10-10-17 _c10-02-16
988			_aSpringer_Medicine_2015
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRC644 .H634 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11576509 _z06-04-17
999			_c82242 _d82242 _x1